WASHINGTON — Republicans on the House Energy and Commerce Committee are gearing up to overhaul a controversial Medicare drug discount program as soon as this quarter, a key Republican tells STAT. That’s a win for drug makers who have long pushed to narrow the scope of the so-called 340B drug discount program.
At the same time, however, the committee will also examine whether to restore a recent $1.6 billion cut to the program, which came under a Trump administration rule that took effect Jan. 1, according to committee Chairman Greg Walden of Oregon. Hospital groups have called the cut “devastating” and have lobbied Congress to reverse it.
Walden and his Republican colleagues on the committee released a report Wednesday, based on a two-year investigation, that recommended a series of legislative and regulatory changes to the 340B program that would likely limit future participation.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect